Zordani Richard A. Jr.

Director Zordani Richard A. Jr. buys 10,000 GALT shares at $0.82; stock down 79.3% from 52-week high; cluster pattern with 2 other insiders

Director Zordani Richard A. Jr. purchased 10,000 shares (10.0K shares) at $0.82, increasing his holdings by 31.2% to 42,083 shares (42.1K shares). This transaction occurs as GALT trades at $0.87, down 79.3% from its 52-week high of $4.20 and down 68.6% over the past 30 days. The purchase is part of a cluster pattern, with 2 other insiders also buying within the past 14 days. Zordani's prior trades at GALT show 3 of 4 buys were well-timed, with 90-day returns of +20.4%, +20.4%, and +22.4%; however, the company remains unprofitable with net income of $-11,220,000.00 over its most recent full fiscal year. The scale and timing of this purchase amid severe price deterioration and negative fundamentals warrant attention to whether the insider activity signals expected recovery or reflects other motivations.

Director Zordani Richard A. Jr. bought 3,500 shares at $2.30 across 3 transactions on Aug 22–23 for $8,050.00

Richard A. Zordani Jr., a director at Galectin Therapeutics, executed 3 separate open-market purchases totaling 3,500 shares for $8,050.00 at a blended average price of $2.30 on August 22–23, 2024, increasing his holdings by 12.2% from 28,583 to 32,083 shares. The stock currently trades at $2.43, down 5.1% over the past 30 days and down 13.8% over 90 days, positioning the purchase roughly 42.1% below the 52-week high. His prior purchase at this ticker on 2024-04-30 resulted in a 90-day return of -27.0%, and across his open-market history (1 prior buy), his average 90-day return is -27.0% with a 0.00% win rate. The company posted a full-year net income of $-12,371,000.00 and is currently unprofitable, adding fundamental pressure to an already challenged price environment.